Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Income from Continuing Operations (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Income from Continuing Operations for 16 consecutive years, with 651482.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Income from Continuing Operations rose 41.72% year-over-year to 651482.0, compared with a TTM value of 3189853.0 through Sep 2025, up 32.76%, and an annual FY2024 reading of 4736365.0, down 53.84% over the prior year.
  • Income from Continuing Operations was 651482.0 for Q3 2025 at China Pharma Holdings, down from 528367.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 475976.0 in Q1 2023 and bottomed at 1438130.0 in Q2 2024.
  • Average Income from Continuing Operations over 5 years is 902785.32, with a median of 826669.0 recorded in 2021.
  • The sharpest move saw Income from Continuing Operations crashed 6418.56% in 2021, then surged 63.26% in 2025.
  • Year by year, Income from Continuing Operations stood at 980719.0 in 2021, then dropped by 28.9% to 1264184.0 in 2022, then increased by 2.53% to 1232213.0 in 2023, then grew by 0.63% to 1224432.0 in 2024, then surged by 46.79% to 651482.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for CPHI at 651482.0 in Q3 2025, 528367.0 in Q2 2025, and 785572.0 in Q1 2025.